Dimensional Fund Advisors LP Purchases 233,119 Shares of Haemonetics Corporation $HAE

Dimensional Fund Advisors LP grew its stake in Haemonetics Corporation (NYSE:HAE) by 21.3% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,326,057 shares of the medical instruments supplier’s stock after purchasing an additional 233,119 shares during the period. Dimensional Fund Advisors LP’s holdings in Haemonetics were worth $74,731,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Quantinno Capital Management LP increased its position in Haemonetics by 9.0% during the 2nd quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after purchasing an additional 289 shares during the period. UMB Bank n.a. lifted its holdings in shares of Haemonetics by 110.9% in the fourth quarter. UMB Bank n.a. now owns 582 shares of the medical instruments supplier’s stock valued at $47,000 after purchasing an additional 306 shares in the last quarter. Cardinal Capital Management grew its holdings in shares of Haemonetics by 1.5% in the fourth quarter. Cardinal Capital Management now owns 22,442 shares of the medical instruments supplier’s stock valued at $1,799,000 after acquiring an additional 321 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of Haemonetics during the 4th quarter worth approximately $26,000. Finally, Leonteq Securities AG bought a new stake in shares of Haemonetics in the fourth quarter valued at approximately $30,000. 99.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on HAE. Weiss Ratings upgraded shares of Haemonetics from a “sell (d+)” rating to a “hold (c-)” rating in a report on Thursday, June 25th. BTIG Research reaffirmed a “buy” rating and issued a $84.00 price target on shares of Haemonetics in a research note on Friday, June 26th. Barrington Research reduced their target price on Haemonetics from $94.00 to $89.00 and set an “outperform” rating on the stock in a report on Tuesday, May 12th. Citigroup reissued a “buy” rating on shares of Haemonetics in a research report on Wednesday. Finally, Robert W. Baird set a $67.00 price target on Haemonetics in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $78.89.

Haemonetics Stock Performance

Shares of HAE stock opened at $85.51 on Friday. Haemonetics Corporation has a 12-month low of $47.31 and a 12-month high of $87.32. The business’s fifty day simple moving average is $75.11 and its 200-day simple moving average is $66.20. The company has a current ratio of 2.95, a quick ratio of 1.87 and a debt-to-equity ratio of 1.53. The company has a market cap of $3.89 billion, a PE ratio of 42.33, a PEG ratio of 1.71 and a beta of 0.52.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a return on equity of 27.30% and a net margin of 7.29%.The firm had revenue of $346.35 million during the quarter, compared to analysts’ expectations of $336.83 million. During the same quarter last year, the firm earned $1.24 EPS. The business’s quarterly revenue was up 4.8% on a year-over-year basis. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. Analysts expect that Haemonetics Corporation will post 5.21 earnings per share for the current fiscal year.

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.